NYSE:GKOS Glaukos (GKOS) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free GKOS Stock Alerts $101.06 +2.11 (+2.13%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$98.31▼$101.2450-Day Range$84.31▼$101.1952-Week Range$45.38▼$102.33Volume351,098 shsAverage Volume666,773 shsMarket Capitalization$5.07 billionP/E RatioN/ADividend YieldN/APrice Target$99.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Glaukos alerts: Email Address Glaukos MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside1.2% Downside$99.80 Price TargetShort InterestBearish6.95% of Shares Sold ShortDividend StrengthN/ASustainability-0.90Upright™ Environmental ScoreNews Sentiment0.52Based on 5 Articles This WeekInsider TradingSelling Shares$22.86 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.18) to ($1.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.44 out of 5 starsMedical Sector271st out of 909 stocksSurgical & Medical Instruments Industry31st out of 94 stocks 2.4 Analyst's Opinion Consensus RatingGlaukos has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageGlaukos has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.95% of the outstanding shares of Glaukos have been sold short.Short Interest Ratio / Days to CoverGlaukos has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Glaukos has recently decreased by 4.64%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldGlaukos does not currently pay a dividend.Dividend GrowthGlaukos does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlaukos has received a 65.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical laser systems", "Medical technology engineering", and "Surgical instruments" products. See details.Environmental SustainabilityThe Environmental Impact score for Glaukos is -0.90. Previous Next 2.5 News and Social Media Coverage News SentimentGlaukos has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Glaukos this week, compared to 4 articles on an average week.Search Interest3 people have searched for GKOS on MarketBeat in the last 30 days. MarketBeat FollowsOnly 3 people have added Glaukos to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Glaukos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,857,372.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Glaukos is held by insiders.Percentage Held by Institutions99.04% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Glaukos are expected to grow in the coming year, from ($2.18) to ($1.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Glaukos is -36.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Glaukos is -36.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlaukos has a P/B Ratio of 10.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Glaukos Stock (NYSE:GKOS)Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.Read More GKOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GKOS Stock News HeadlinesApril 11, 2024 | insidertrades.comGlaukos Co. (NYSE:GKOS) COO Sells $6,008,206.47 in StockApril 10, 2024 | insidertrades.comGlaukos Co. (NYSE:GKOS) CFO Alex R. Thurman Sells 1,372 SharesApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 6, 2024 | insidertrades.comGlaukos Co. (NYSE:GKOS) COO Sells $19,314.00 in StockApril 4, 2024 | insidertrades.comGlaukos Co. (NYSE:GKOS) CFO Alex R. Thurman Sells 474 SharesApril 22, 2024 | americanbankingnews.comGlaukos (NYSE:GKOS) vs. Revolutions Medical (OTCMKTS:RMCP) Head to Head SurveyApril 21, 2024 | americanbankingnews.comGlaukos (NYSE:GKOS) Trading 3.4% Higher April 19, 2024 | americanbankingnews.comGlaukos Co. (NYSE:GKOS) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 16, 2024 | businesswire.comGlaukos Announces the Release of its 2023 Sustainability ReportApril 13, 2024 | americanbankingnews.comGlaukos (NYSE:GKOS) PT Raised to $100.00April 13, 2024 | ca.news.yahoo.comSpeaker Johnson welcomes Japanese PM Kishida and his wife to the CapitolApril 11, 2024 | finance.yahoo.comIs Now The Time To Look At Buying Glaukos Corporation (NYSE:GKOS)?April 11, 2024 | investing.comGlaukos CFO sells over $163k in company stockApril 10, 2024 | finance.yahoo.comGlaukos to Release First Quarter 2024 Financial Results after Market Close on May 1April 10, 2024 | businesswire.comGlaukos to Release First Quarter 2024 Financial Results after Market Close on May 1April 3, 2024 | msn.comGlaukos gains on permanent J-code for iDose TRApril 3, 2024 | finance.yahoo.comGlaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)April 1, 2024 | finance.yahoo.comGlaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual MeetingMarch 25, 2024 | msn.comMasimo considering JV for consumer division: WSJMarch 25, 2024 | msn.comActivist Politan plans second proxy fight at Masimo (update)March 22, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Glaukos (GKOS)March 22, 2024 | markets.businessinsider.com5 Analysts Have This To Say About GlaukosMarch 22, 2024 | finance.yahoo.comGlaukos (GKOS) Down 4.3% Since Last Earnings Report: Can It Rebound?March 18, 2024 | finance.yahoo.comGKOS Apr 2024 140.000 callMarch 16, 2024 | finance.yahoo.comGKOS Apr 2024 92.500 putMarch 16, 2024 | ca.finance.yahoo.comGKOS Apr 2024 80.000 putSee More Headlines Receive GKOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today4/23/2024Next Earnings (Confirmed)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:GKOS CUSIPN/A CIK1192448 Webwww.glaukos.com Phone(949) 367-9600Fax949-367-9984Employees907Year FoundedN/APrice Target and Rating Average Stock Price Target$99.80 High Stock Price Target$120.00 Low Stock Price Target$65.00 Potential Upside/Downside-1.2%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-134,660,000.00 Net Margins-42.79% Pretax Margin-42.49% Return on Equity-22.67% Return on Assets-11.50% Debt Debt-to-Equity Ratio0.77 Current Ratio5.34 Quick Ratio4.78 Sales & Book Value Annual Sales$314.71 million Price / Sales16.12 Cash FlowN/A Price / Cash FlowN/A Book Value$9.46 per share Price / Book10.68Miscellaneous Outstanding Shares50,190,000Free Float46,976,000Market Cap$5.07 billion OptionableOptionable Beta1.08 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Thomas William Burns (Age 63)Chairman & CEO Comp: $1.5MMr. Joseph E. Gilliam (Age 48)President & COO Comp: $974.59kMr. Alex R. Thurman (Age 54)Senior VP & CFO Comp: $373.4kMr. Chris M. Calcaterra (Age 64)Executive Vice President of Global Commercial Operations Comp: $198.66kDr. Tomas Navratil Ph.D. (Age 47)Chief Development Officer Comp: $721.51kDr. Mory Gharib Ph.D.Co-FounderMr. Christopher William LewisVice President of Investor Relations & Corporate AffairsMs. Diana A. SchererVP of Compliance & Deputy General CounselMs. Michele M. AllegrettoSenior Vice President of Human ResourcesMs. Jane E. Rady (Age 76)Senior Vice President of Corporate Strategy & Business Development More ExecutivesKey CompetitorsHaemoneticsNYSE:HAEMerit Medical SystemsNASDAQ:MMSIAxonicsNASDAQ:AXNXiRhythm TechnologiesNASDAQ:IRTCInspire Medical SystemsNYSE:INSPView All CompetitorsInsiders & InstitutionsLouisiana State Employees Retirement SystemSold 200 shares on 4/23/2024Ownership: 0.048%Maryland State Retirement & Pension SystemSold 122 shares on 4/20/2024Ownership: 0.035%Taylor Frigon Capital Management LLCSold 494 shares on 4/19/2024Ownership: 0.097%State of Alaska Department of RevenueSold 281 shares on 4/19/2024Ownership: 0.059%Caldwell Sutter Capital Inc.Bought 1,465 shares on 4/19/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions GKOS Stock Analysis - Frequently Asked Questions Should I buy or sell Glaukos stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GKOS shares. View GKOS analyst ratings or view top-rated stocks. What is Glaukos' stock price target for 2024? 9 brokerages have issued 12-month price objectives for Glaukos' shares. Their GKOS share price targets range from $65.00 to $120.00. On average, they expect the company's stock price to reach $99.80 in the next twelve months. This suggests that the stock has a possible downside of 1.2%. View analysts price targets for GKOS or view top-rated stocks among Wall Street analysts. How have GKOS shares performed in 2024? Glaukos' stock was trading at $79.49 at the beginning of 2024. Since then, GKOS shares have increased by 27.1% and is now trading at $101.06. View the best growth stocks for 2024 here. When is Glaukos' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our GKOS earnings forecast. How can I listen to Glaukos' earnings call? Glaukos will be holding an earnings conference call on Wednesday, May 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Glaukos' earnings last quarter? Glaukos Co. (NYSE:GKOS) issued its quarterly earnings data on Wednesday, February, 21st. The medical instruments supplier reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.07. The medical instruments supplier earned $82.40 million during the quarter, compared to the consensus estimate of $81 million. Glaukos had a negative trailing twelve-month return on equity of 22.67% and a negative net margin of 42.79%. The business's revenue for the quarter was up 15.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.53) earnings per share. What ETFs hold Glaukos' stock? ETFs with the largest weight of Glaukos (NYSE:GKOS) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), Alger Weatherbie Enduring Growth ETF (AWEG), SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P SmallCap Momentum ETF (XSMO), Fidelity Disruptive Medicine ETF (FMED), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Principal Healthcare Innovators ETF (BTEC) and iShares S&P Small-Cap 600 Growth ETF (IJT). What guidance has Glaukos issued on next quarter's earnings? Glaukos issued an update on its FY 2024 earnings guidance on Friday, February, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $350.0 million-$360.0 million, compared to the consensus revenue estimate of $352.7 million. What is Thomas W. Burns' approval rating as Glaukos' CEO? 10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Glaukos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA). When did Glaukos IPO? Glaukos (GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers. Who are Glaukos' major shareholders? Glaukos' stock is owned by many different retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.34%), Taylor Frigon Capital Management LLC (0.10%), State of Alaska Department of Revenue (0.06%), Louisiana State Employees Retirement System (0.05%), Maryland State Retirement & Pension System (0.04%) and SteelPeak Wealth LLC (0.01%). Insiders that own company stock include Alex R Thurman, Gilbert H Kliman, Joseph E Gilliam, Joseph E Gilliam, Marc Stapley, Mark J Foley and Thomas William Burns. View institutional ownership trends. How do I buy shares of Glaukos? Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:GKOS) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Glaukos Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
